Navigation Links
Vaginal Gel That Protects Against HIV To Hit The Markets By 2010

According to the researchers, a vaginal gel, which is said to be much safer and more effective in protecting women against HIV, the virus that causes AIDS// expected to hit the markets by 2010.

Currently, microbe-killing vaginal gels are being tested in a number of clinical trials involving thousands of women. Results should be available within two years, the Associated Press reported.

According to foodconsumer.org, if the trials prove the gels are effective and if governments fast-track their approval, they could be on the market as early as 2010, Gita Ramjee, director of the HIV prevention research unit at South Africa's Medical Research Council, said at a news conference in Cape Town before an international conference on microbicides.

More than 1,000 scientists and researchers are attending the conference, which is co-sponsored by the World Health Organization.

In many parts of the world, HIV infections are increasing more rapidly among women than men. Half of all adults with HIV are female, according to the United Nations.

A microbicide that's 60 percent effective against HIV that's used by only 20 percent of women in 73 developing countries could prevent 2.5 million HIV infections, the London School of Tropical Hygiene has calculated, the AP reported.


'"/>




Page: 1

Related medicine news :

1. Vaginal Birth After C-section Dangerous For Both Mother And Baby
2. PET Scanner detects more Vaginal cancer than CT scans
3. Vaginal Vaccine may prevent periodic infections
4. Vaginal atrophy drug Ospemifene found effective in breast cancer Prevention
5. Increased Risk Of HIV Transmission Following Vaginal Washing
6. Risk Of AIDS Rises With Vaginal Washes
7. Vaginal massage during pregnancy avoids Episiotomy procedure
8. Vaginal Delivery Should Be an Option after Multiple Cesareans
9. New Laparoscopic Surgery to Correct Vaginal Vault Prolapse Is Effectual Than the Conventional Surgery
10. Extra Vaginal Bleed After ‘C’ Section Can be Prevented By Contraceptive Pils
11. Risk of Hemorrhage Increased in Vaginally Born Babies
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/23/2017)... ... March 23, 2017 , ... The TouchPoint Solution, home of Buzzies ... stress and anxiety. , “Buzzies change the way we interact with stress and ... , Since its launch date in December 2016, The TouchPoint Solution has sold more ...
(Date:3/23/2017)... ... , ... ?This conference will prominently feature 150+ Hospital and Health System Executive Speakers including: , ... , 43rd President of the United States of America: George W. Bush , ... Out of the Ring: Sugar Ray Leonard , JD, Chairperson, McGuireWoods LLP: Amber ...
(Date:3/23/2017)... ... 23, 2017 , ... It’s that time of year again! Time to think ... summer internships , which can be frustrating when they don’t even know how to ... a boutique public relations firm outside of Philadelphia, have offered these three tips to ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... skincare products, was awarded as winners of American Dreams & Good Housekeeping Seal ... hosted jointly by HSN and Good Housekeeping. , Steven Wang, MD ., ...
(Date:3/23/2017)... , ... March 23, 2017 , ... News Advisory/Interview Opportunity ... has helped score a major victory in Europe for public health and the environment ... , Based on rigorous scientific research and the overwhelming support of European citizens, the ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... 23, 2017  Cornerstone Pharmaceuticals, Inc., a ... milestone today.  Following successful End-of-Phase I (EOP1) ... and Drug Administration (FDA), the Company has ... path forward to conduct pivotal trials of ... acute myeloid leukemia (AML) and pancreatic cancer. ...
(Date:3/23/2017)... March 23, 2017 Piramal ... Limited, anuncia el nombramiento de Stuart E. ... plataforma de servicios integrados completa para su base ... cargo clave en el crecimiento y ejecución de ... responsable de impulsar todas las actividades de desarrollo ...
(Date:3/23/2017)... Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... a Phase 1 study of MM-310 in solid tumors. ... novel taxane and targets the EphA2 receptor, a protein ... major tumor types, including prostate, ovarian, bladder, gastric, pancreatic ... study is an important step in evaluating MM-310,s safety ...
Breaking Medicine Technology: